Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Curr Pain Headache Rep ; 25(1): 6, 2021 Jan 25.
Article in English | MEDLINE | ID: mdl-33495883

ABSTRACT

PURPOSE OF REVIEW: Loin pain hematuria syndrome (LPHS) is rare and seldom diagnosed, yet it has a particularly significant impact on those affected. This is a review of the latest and seminal evidence of the pathophysiology and diagnosis of LPHS and presents the typical clinical presentation and treatment options available. RECENT FINDINGS: LPHS is typically found in young women with characteristic symptoms, including severe recurrent flank pain and gross or microscopic hematuria. The majority of patients will experience crippling pain for many years without effective therapy, often requiring frequent use of narcotic medication. However, the lack of conclusive pathophysiology, in conjunction with the rarity of LPHS, has prohibited the development and trial of definitive treatment options. Nevertheless, in order to combat this rare but severe disease, management strategies have continued to evolve, ranging from conservative measures to invasive procedures. This review presents an overview of the current hypotheses on the pathophysiology of LPHS in addition to summarizing the management strategies that have been utilized. Only 30% of LPHS patients will experience spontaneous resolution, whereas the majority will continue to face chronic, crippling pain. Several methods of treatment, including invasive and non-invasive, may provide an improved outcome to these patients. Treatment should be individually tailored and multi-disciplinary in nature. Further research is required to further elucidate the pathophysiology and develop new, specific, treatment options.


Subject(s)
Flank Pain/therapy , Hematuria/therapy , Age Distribution , Analgesics, Opioid/therapeutic use , Anesthetics, Local/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Bupivacaine/administration & dosage , Capsaicin/administration & dosage , Denervation , Electric Stimulation Therapy , Flank Pain/complications , Flank Pain/epidemiology , Flank Pain/physiopathology , Ganglia, Spinal , Hematuria/complications , Hematuria/epidemiology , Hematuria/physiopathology , Humans , Hypnosis , Infusions, Spinal , Kidney/innervation , Nephrectomy , Neuromuscular Agents/therapeutic use , Pulsed Radiofrequency Treatment , Renal Dialysis , Sensory System Agents/administration & dosage , Sex Distribution , Splanchnic Nerves , Sympathectomy , Syndrome , Transplantation, Autologous , Ureter
3.
BMJ Case Rep ; 20172017 Dec 20.
Article in English | MEDLINE | ID: mdl-29269368

ABSTRACT

Intrathecal baclofen (ITB) delivery via an implanted pump is frequently used for the treatment of spasticity. This is an effective and safe neurosurgical and pharmacological intervention associated with an improvement in patient quality of life. There is, however, a risk of device-related infection. We present a patient with pump-site infection and Escherichia coli meningitis secondary to transcolonic perforation of an intrathecal baclofen pump catheter. While this is rare, we review the intraoperative precautions and best practices that should be taken to prevent and manage this unusual complication.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Baclofen/administration & dosage , Catheterization/adverse effects , Catheters, Indwelling/adverse effects , Infusion Pumps, Implantable/adverse effects , Intestinal Perforation/microbiology , Meningitis, Escherichia coli/microbiology , Multiple Sclerosis/drug therapy , Muscle Relaxants, Central/administration & dosage , Catheters, Indwelling/microbiology , Device Removal , Disabled Persons , Female , Humans , Iatrogenic Disease , Infusion Pumps, Implantable/microbiology , Infusions, Spinal/adverse effects , Intestinal Perforation/etiology , Meningitis, Escherichia coli/etiology , Microbial Sensitivity Tests , Middle Aged , Recurrence , Treatment Outcome
4.
Mult Scler ; 23(13): 1663-1676, 2017 Nov.
Article in English | MEDLINE | ID: mdl-29115915

ABSTRACT

Neuromodulation, or the utilization of advanced technology for targeted electrical or chemical neuronal stimulation or inhibition, has been expanding in several neurological subspecialties. In the past decades, immune-modulating therapy has been the main focus of multiple sclerosis (MS) research with little attention to neuromodulation. However, with the recent advances in disease-modifying therapies, it is time to shift the focus of MS research to neuromodulation and restoration of function as with other neurological subspecialties. Preliminary research supports the value of intrathecal baclofen pump and functional electrical stimulation in improving spasticity and motor function in MS patients. Deep brain stimulation can improve MS-related tremor and trigeminal neuralgia. Spinal cord stimulation has been shown to be effective against MS-related pain and bladder dysfunction. Bladder overactivity also responds to sacral neuromodulation and posterior tibial nerve stimulation. Despite limited data in MS, transcranial magnetic stimulation and brain-computer interface are promising neuromodulatory techniques for symptom mitigation and neurorehabilitation of MS patients. In this review, we provide an overview of the available neuromodulatory techniques and the evidence for their use in MS.


Subject(s)
Brain-Computer Interfaces , Deep Brain Stimulation/methods , Infusion Pumps, Implantable , Infusions, Spinal/methods , Multiple Sclerosis/rehabilitation , Muscle Relaxants, Central/administration & dosage , Spinal Cord Stimulation/methods , Transcranial Magnetic Stimulation/methods , Transcutaneous Electric Nerve Stimulation/methods , Humans , Infusions, Spinal/instrumentation
5.
Cornea ; 35(4): 576-7, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26807903

ABSTRACT

PURPOSE: This case study reports on 2 novel neuromodulatory approaches in the management of a particularly recalcitrant case of corneal neuropathic pain. METHODS: Report of a case RESULTS: : A 32-year-old woman presented with intractable bilateral dry eye-like symptoms and corneal neuropathic pain after undergoing laser in situ keratomileusis surgery. Extensive ocular and systemic therapies were unsuccessful. Implantation of an electrode for the electrical stimulation of the trigeminal ganglion resulted in complete resolution of symptoms, but pain recurred after lead migration. Implantation of an intrathecal infusion system for fentanyl and bupivacaine delivery at the C1-C2 level resulted in control of her symptoms with excellent pain relief for more than 1 year. CONCLUSIONS: Electrical stimulation of the trigeminal ganglion and a high cervical intrathecal pain pump can be used in the management of corneal neuropathic pain unresponsive to ocular and systemic approaches.


Subject(s)
Bupivacaine/administration & dosage , Corneal Diseases/therapy , Drug Delivery Systems , Electric Stimulation Therapy , Fentanyl/administration & dosage , Trigeminal Ganglion/physiology , Trigeminal Neuralgia/therapy , Adult , Analgesics, Opioid/administration & dosage , Anesthetics, Local/administration & dosage , Combined Modality Therapy , Corneal Diseases/etiology , Dry Eye Syndromes/etiology , Dry Eye Syndromes/therapy , Electrodes, Implanted , Eye Pain/etiology , Eye Pain/therapy , Female , Humans , Infusions, Spinal , Keratomileusis, Laser In Situ/adverse effects , Microscopy, Confocal , Recurrence , Trigeminal Neuralgia/etiology
6.
Mol Neurobiol ; 52(2): 837-45, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26126514

ABSTRACT

Previous studies from our laboratory showed that topical application of growth hormone (GH) induced neuroprotection 5 h after spinal cord injury (SCI) in a rat model. Since nanodelivery of drugs exerts superior neuroprotective effects, a possibility exists that nanodelivery of GH will induce long-term neuroprotection after a focal SCI. SCI induces GH deficiency that is coupled with insulin-like growth factor-1 (IGF-1) reduction in the plasma. Thus, an exogenous supplement of GH in SCI may enhance the IGF-1 levels in the cord and induce neuroprotection. In the present investigation, we delivered TiO2-nanowired growth hormone (NWGH) after a longitudinal incision of the right dorsal horn at the T10-11 segments in anesthetized rats and compared the results with normal GH therapy on IGF-1 and GH contents in the plasma and in the cord in relation to blood-spinal cord barrier (BSCB) disruption, edema formation, and neuronal injuries. Our results showed a progressive decline in IGF-1 and GH contents in the plasma and the T9 and T12 segments of the cord 12 and 24 h after SCI. Marked increase in the BSCB breakdown, as revealed by extravasation of Evans blue and radioiodine, was seen at these time points after SCI in association with edema and neuronal injuries. Administration of NWGH markedly enhanced the IGF-1 levels and GH contents in plasma and cord after SCI, whereas normal GH was unable to enhance IGF-1 or GH levels 12 or 24 h after SCI. Interestingly, NWGH was also able to reduce BSCB disruption, edema formation, and neuronal injuries after trauma. On the other hand, normal GH was ineffective on these parameters at all time points examined. Taken together, our results are the first to demonstrate that NWGH is quite effective in enhancing IGF-1 and GH levels in the cord and plasma that may be crucial in reducing pathophysiology of SCI.


Subject(s)
Growth Hormone/therapeutic use , Insulin-Like Growth Factor I/analysis , Nanowires , Neuroprotective Agents/therapeutic use , Spinal Cord Injuries/drug therapy , Administration, Topical , Animals , Drug Delivery Systems , Drug Implants , Edema/etiology , Edema/prevention & control , Evans Blue/pharmacokinetics , Growth Hormone/administration & dosage , Growth Hormone/analysis , Growth Hormone/pharmacokinetics , Infusion Pumps , Infusions, Spinal , Iodine Radioisotopes/pharmacokinetics , Male , Neurons/pathology , Neuroprotective Agents/administration & dosage , Neuroprotective Agents/pharmacokinetics , Permeability , Rats , Rats, Sprague-Dawley , Recombinant Proteins/administration & dosage , Recombinant Proteins/analysis , Recombinant Proteins/pharmacokinetics , Recombinant Proteins/therapeutic use , Spinal Cord/blood supply , Spinal Cord/chemistry , Spinal Cord/pathology , Spinal Cord Injuries/blood , Spinal Cord Injuries/complications , Spinal Cord Injuries/physiopathology , Thoracic Vertebrae
7.
Int J Nurs Pract ; 21(6): 797-804, 2015 Dec.
Article in English | MEDLINE | ID: mdl-24689780

ABSTRACT

Cancer and its treatment are stressful and reduce the quality of life in children. The aim of this study was to investigate the effect of massage therapy on pain and anxiety arising from intrathecal therapy or bone marrow aspiration in children with cancer. We conducted a controlled pretest/posttest quasi-experimental study at a paediatric oncology unit in Turkey. Twenty-five children were enrolled in this study. Their pain and anxiety were determined using a visual analogue scale. When the pretest and posttest pain and anxiety levels of the groups were compared, no statistically significant difference was found (P > 0.05). It was determined that pain and anxiety levels in the experimental group decreased significantly. This study provides preliminary evidence for the effectiveness in children of massage in reducing pain and anxiety arising from intrathecal therapy or bone marrow aspiration.


Subject(s)
Anxiety/prevention & control , Bone Marrow Examination/adverse effects , Massage , Neoplasms/complications , Neoplasms/psychology , Pain/prevention & control , Adolescent , Anxiety/etiology , Bone Marrow Examination/psychology , Child , Child, Preschool , Female , Humans , Infusions, Spinal/adverse effects , Infusions, Spinal/psychology , Injections, Spinal/adverse effects , Injections, Spinal/psychology , Male , Neoplasms/therapy , Pain/etiology
8.
J Lipid Res ; 55(12): 2450-7, 2014 Dec.
Article in English | MEDLINE | ID: mdl-24721741

ABSTRACT

The postinjury period of glucose metabolic depression is accompanied by adenosine triphosphate decreases, increased flux of glucose through the pentose phosphate pathway, free radical production, activation of poly-ADP ribose polymerase via DNA damage, and inhibition of glyceraldehyde dehydrogenase (a key glycolytic enzyme) via depletion of the cytosolic NAD pool. Under these post-brain injury conditions of impaired glycolytic metabolism, glucose becomes a less favorable energy substrate. Ketone bodies are the only known natural alternative substrate to glucose for cerebral energy metabolism. While it has been demonstrated that other fuels (pyruvate, lactate, and acetyl-L-carnitine) can be metabolized by the brain, ketones are the only endogenous fuel that can contribute significantly to cerebral metabolism. Preclinical studies employing both pre- and postinjury implementation of the ketogenic diet have demonstrated improved structural and functional outcome in traumatic brain injury (TBI) models, mild TBI/concussion models, and spinal cord injury. Further clinical studies are required to determine the optimal method to induce cerebral ketone metabolism in the postinjury brain, and to validate the neuroprotective benefits of ketogenic therapy in humans.


Subject(s)
Brain Injuries/diet therapy , Cerebral Cortex/metabolism , Diet, Ketogenic , Energy Metabolism , Evidence-Based Medicine , Ketone Bodies/metabolism , Neurons/metabolism , Animals , Brain Concussion/diet therapy , Brain Concussion/metabolism , Brain Concussion/therapy , Brain Injuries/metabolism , Brain Injuries/therapy , Cerebral Cortex/injuries , Diet, Ketogenic/adverse effects , Dietary Supplements , Down-Regulation , Glycolysis , Humans , Infusions, Intravenous , Infusions, Spinal , Ketone Bodies/administration & dosage , Ketone Bodies/therapeutic use , Ketones/administration & dosage , Ketones/metabolism , Ketones/therapeutic use , Spinal Cord/metabolism , Spinal Cord Injuries/diet therapy , Spinal Cord Injuries/metabolism , Spinal Cord Injuries/therapy
9.
Eur J Pharmacol ; 683(1-3): 204-10, 2012 May 15.
Article in English | MEDLINE | ID: mdl-22445525

ABSTRACT

During a migraine attack capsaicin-sensitive trigeminal sensory nerves release calcitonin gene-related peptide (CGRP), producing cranial vasodilatation and central nociception; hence, trigeminal inhibition may prevent this vasodilatation and abort migraine headache. This study investigated the role of spinal α2-adrenoceptors and their subtypes (i.e. α(2A), α(2B) and/or α(2C)-adrenoceptors) in the inhibition of the canine external carotid vasodilator responses to capsaicin. Anaesthetized vagosympathectomized dogs were prepared to measure arterial blood pressure, heart rate and external carotid conductance. The thyroid artery was cannulated for one-min intracarotid infusions of capsaicin, α-CGRP and acetylcholine. A cannula was inserted intrathecally for spinal (C1-C3) administration of 2-amino-6-ethyl-4,5,7,8-tetrahydro-6H-oxazolo-[5,4-d]-azepin-dihydrochloride (B-HT 933; a selective α2-adrenoceptor agonist) and/or the α2-adrenoceptor antagonists rauwolscine (α(2A/2B/2C)), 2-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,3-dihydro-1-methyl-1H-isoindole maleate (BRL44408; α(2A)), imiloxan (α(2B)) or acridin-9-yl-[4-(4-methylpiperazin-1-yl)-phenyl]amine (JP-1302; α(2C)). Infusions of capsaicin, α-CGRP and acetylcholine dose-dependently increased the external carotid conductance. Intrathecal B-HT 933 (1000 and 3100 µg) inhibited the vasodilator responses to capsaicin, but not those to α-CGRP or acetylcholine. This inhibition, abolished by rauwolscine (310 µg), was: (i) unaffected by 3,100 µg imiloxan; (ii) partially blocked by 310 µg of BRL44408 or 100 µg of JP-1302; and (iii) abolished by 1,000 µg of BRL44408 or 310 µg of JP-1302. Thus, intrathecal B-HT 933 inhibited the external carotid vasodilator responses to capsaicin. This response, mediated by spinal α2-adrenoceptors unrelated to the α(2B)-adrenoceptor subtype, resembles the pharmacological profile of α(2C)-adrenoceptors and, to a lesser extent, α(2A)-adrenoceptors.


Subject(s)
Adrenergic alpha-2 Receptor Antagonists/therapeutic use , Carotid Artery, External/drug effects , Disease Models, Animal , Migraine Disorders/drug therapy , Receptors, Adrenergic, alpha-2/metabolism , Spinal Cord/drug effects , Vasoconstrictor Agents/therapeutic use , Acetylcholine/metabolism , Adrenergic alpha-2 Receptor Antagonists/administration & dosage , Adrenergic alpha-2 Receptor Antagonists/chemistry , Analgesics, Non-Narcotic/administration & dosage , Analgesics, Non-Narcotic/antagonists & inhibitors , Analgesics, Non-Narcotic/therapeutic use , Animals , Calcitonin Gene-Related Peptide/metabolism , Capsaicin/antagonists & inhibitors , Capsaicin/toxicity , Carotid Artery, External/physiology , Cervical Vertebrae , Dogs , Hemodynamics/drug effects , Infusions, Spinal , Male , Migraine Disorders/chemically induced , Migraine Disorders/metabolism , Protein Isoforms/antagonists & inhibitors , Protein Isoforms/metabolism , Receptors, Adrenergic, alpha-2/chemistry , Regional Blood Flow/drug effects , Spinal Cord/metabolism , Vasoconstrictor Agents/administration & dosage , Vasoconstrictor Agents/antagonists & inhibitors , Vasodilator Agents/antagonists & inhibitors , Vasodilator Agents/toxicity
10.
Am J Surg ; 202(6): 765-9; discussion 770, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22018440

ABSTRACT

BACKGROUND: Postoperative pain management with a continuous preperitoneal infusion (CPI) for locoregional anesthesia has been shown to have improved postoperative outcomes. This is the first direct comparison of CPI versus epidural infusion (EPI), both in conjunction with systemic analgesia. METHODS: A retrospective review was performed of midline laparotomy cases, comparing the use of CPI with systemic patient-controlled analgesia to EPI with systemic patient-controlled analgesia for postoperative outcomes. RESULTS: A total of 240 cases from 2007 to 2009 were reviewed. There were 41.3% using CPI and 58.7% with EPI. There were no differences with respect to age, body mass index, or American Society of Anesthesiologists score between CPI and EPI cases. In a multivariate model, total hospital stay was 2 days shorter for the CPI group (P < .001), and the total admission cost was less for CPI (by $6,164; P < .001). CONCLUSIONS: The use of CPI results in decreased length of hospital stay, decreased number of days with a Foley catheter, and lower hospital costs, compared with EPI use. These findings show that the routine use of CPI for pain management after laparotomy is a safe alternative to EPI.


Subject(s)
Anesthesia, Epidural/methods , Anesthesia, Local/methods , Anesthetics/administration & dosage , Laparotomy/methods , Pain, Postoperative/therapy , Female , Follow-Up Studies , Humans , Infusions, Parenteral/statistics & numerical data , Infusions, Spinal/statistics & numerical data , Male , Middle Aged , Pain Measurement , Retrospective Studies , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL